Gilead Sciences Receives a Hold from Maxim Group

By Carrie Williams

Maxim Group analyst Gabrielle Zhou reiterated a Hold rating on Gilead Sciences (NASDAQ: GILD) today. The company’s shares opened today at $66.54.

Zhou wrote:

“Gilead announced positive data for GS-0976 at the 53rd Annual Meeting of the European Association for the Study of the Liver (EASL) during the International Liver Congress (ILC), demonstrating significant improvements in liver fat content and noninvasive markers of fibrosis in 10 NASH patients.”

According to, Zhou is a 1-star analyst with an average return of -2.4% and a 31.6% success rate. Zhou covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Sciclone Pharmaceuticals, and Mateon Therapeutics Inc.

Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $82.57.

Based on Gilead Sciences’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $7.31 billion and quarterly net profit of $3.11 billion. In comparison, last year the company earned revenue of $7.71 billion and had a net profit of $3.57 billion.

Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. Earlier this month, John C. Martin, the Chairman & CEO of GILD sold 73,333 shares for a total of $4,925,901.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need. It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology & oncology, and cardiovascular & inflammation as well as respiratory diseases. The company’s products include Descovy, Odefsey, Genvoya, Stribild, Complera, Atripla, Truvada, Viread, Emtriva, Tybost, Vitekta, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, Hepsera, Zydelig, Letairis, Ranexa, Lexiscan, Cayston, Tamiflu, AmBisome and Macugen. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.